LBRX financial statements
The full income statement, balance sheet, and cash-flow statement for LB Pharmaceuticals Inc (LBRX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 |
|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | |
| 30.4M-53.1% | 64.8M | ||
| Research & development | 16.7M-67.3% | 51.2M | |
| Selling, general & administrative | 13.7M+0.0% | 13.7M | |
| General & administrative | 13.7M+0.0% | 13.7M | |
| Interest & investment income | 3.92M+127.8% | 1.72M | |
| Other non-operating income | 5.20M+200.8% | 1.73M | |
| Pre-tax income | -25.2M+60.1% | -63.1M | |
| Income tax | 1.00K+0.0% | 1.00K | |
| -25.2M+60.1% | -63.1M | ||
| Net income to common | -25.2K+60.1% | -63.1K | |
| -$3.13+98.2% | -$176.15 | ||
| EPS (basic) | -$3.13+98.2% | -$176.15 | |
| Weighted-avg shares (basic) | 8.05M+2145.8% | 358K | |
| Weighted-avg shares (diluted) | 8.05M+2145.8% | 358K | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | |
| 308M+968.0% | 28.9M | ||
| Cash & equivalents | 250M+988.8% | 23.0M | |
| Short-term investments | 45.0M+797.0% | 5.02M | |
| Cash & short-term investments | 295M+1060.2% | 25.4M | |
| Prepaid expenses | 13.2M+1402.2% | 880K | |
| 313M+833.2% | 33.5M | ||
| Property, plant & equipment | 1.58M-15.0% | 1.86M | |
| Operating lease right-of-use | 2.15M-6.4% | 2.30M | |
| 7.44M-8.2% | 8.11M | ||
| Accounts payable | 2.13M-8.3% | 2.32M | |
| Accrued liabilities | 4.58M-13.5% | 5.30M | |
| Current lease liability | 730K+49.9% | 487K | |
| 11.6M-15.9% | 13.8M | ||
| Non-current lease liability | 2.84M-11.7% | 3.22M | |
| Operating lease liability (total) | 3.57M-3.6% | 3.70M | |
| 301M+418.7% | -94.6M | ||
| Common stock | 3.00K+200.0% | 1.00K | |
| Additional paid-in capital | 431M+4359.6% | 9.66M | |
| Retained earnings | -130M-24.2% | -104M | |
| Accumulated other comprehensive income | 168K+51.4% | 111K | |
| Total liabilities & equity | 313M+833.2% | 33.5M | |
| Common shares issued | 25.3M+9953.2% | 252K | |
| Common shares outstanding | 25.3M+9953.2% | 252K | |
| Shares outstanding (cover) | 28.7M | — | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | |
| -35.2M+33.6% | -53.1M | ||
| Depreciation & amortization | 321K+252.7% | 91.0K | |
| Share-based compensation | 4.19M+35.6% | 3.09M | |
| Deferred income taxes | 0.00 | 0.00 | |
| -39.9M-271.7% | 23.2M | ||
| Capital expenditure | 52.0K-93.2% | 769K | |
| Free cash flow | -35.3M+34.5% | -53.8M | |
| Acquisitions | 0.00 | 0.00 | |
| Sales/maturities of investments | 2.50M-91.7% | 30.1M | |
| 303M+689.7% | 38.3M | ||
| Long-term debt issued | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | |
| Net change in cash | 227M+2577.0% | 8.50M | |
| Income taxes paid | 1.00K+0.0% | 1.00K | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | |
| Market cap | 638M | — | |
| P/B | 2.1× | — | |
| Source filing | 10-K | 10-K |
About this data
Source: LBRX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all LBRX filings on SEC EDGAR → Not investment advice.